BRPI0416683A - muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21 - Google Patents

muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21

Info

Publication number
BRPI0416683A
BRPI0416683A BRPI0416683-3A BRPI0416683A BRPI0416683A BR PI0416683 A BRPI0416683 A BR PI0416683A BR PI0416683 A BRPI0416683 A BR PI0416683A BR PI0416683 A BRPI0416683 A BR PI0416683A
Authority
BR
Brazil
Prior art keywords
fgf
growth factor
fibroblast growth
human
polynucleotide
Prior art date
Application number
BRPI0416683-3A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0416683A publication Critical patent/BRPI0416683A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)

Abstract

"MUTEìNA DE FATOR DE CRESCIMENTO DE FIBROBLASTO DE HUMANO 21 (FGF-21), OU UM SEU PEPTìDEO BIOLOGICAMENTE ATIVO, POLINUCLEOTìDEO, VETOR DE EXPRESSãO, CéLULA HOSPEDEIRA, PROCESSO PARA PRODUZIR UM POLIPEPTìDEO, COMPOSIçãO FARMACêUTICA, MéTODO PARA TRATAR UM PACIENTE, E, USO DA MUTEìNA FGF-21". A presente invenção refere-se às novas muteínas de fator de crescimento de fibroblasto de humano 21 com propriedades farmacêuticas melhoradas. São descritas tanto proteínas quanto espécies de ácido nucleico codificadoras respectivas. A invenção também tem por modalidades vetores e células hospedeiras para a propagação de citadas seqüências de ácido nucleico e a produção de citadas muteínas. Também são descritos métodos para tratar diabetes de tipo 2, obesidade, síndrome metabólica, e para reduzir a mortalidade e a morbidez de pacientes criticamente doentes.
BRPI0416683-3A 2003-12-10 2004-12-01 muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21 BRPI0416683A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52858203P 2003-12-10 2003-12-10
PCT/US2004/037200 WO2005061712A1 (en) 2003-12-10 2004-12-01 Muteins of fibroblast growth factor 21

Publications (1)

Publication Number Publication Date
BRPI0416683A true BRPI0416683A (pt) 2007-01-30

Family

ID=34710086

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416683-3A BRPI0416683A (pt) 2003-12-10 2004-12-01 muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21

Country Status (14)

Country Link
US (2) US7491697B2 (pt)
EP (2) EP1702067A1 (pt)
JP (1) JP4477013B2 (pt)
KR (1) KR20060135648A (pt)
CN (1) CN1890371A (pt)
AR (1) AR046877A1 (pt)
AU (1) AU2004303783A1 (pt)
BR (1) BRPI0416683A (pt)
CA (1) CA2549249A1 (pt)
EA (1) EA200601121A1 (pt)
IL (1) IL175736A0 (pt)
NO (1) NO20062662L (pt)
TW (1) TW200520772A (pt)
WO (1) WO2005061712A1 (pt)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
WO2006014899A2 (en) 2004-07-26 2006-02-09 Dow Global Technologies Inc. Process for improved protein expression by strain engineering
US7622445B2 (en) * 2004-09-02 2009-11-24 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP2161281A1 (en) * 2004-09-02 2010-03-10 Eli Lilly & Company Muteins of fibroblast growth factor 21
JP2008522617A (ja) * 2004-12-14 2008-07-03 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
CA2633554C (en) 2005-12-22 2012-11-13 Genetech, Inc. Recombinant production of heparin binding proteins
CA2656835C (en) 2006-07-14 2017-12-19 Genentech, Inc. Refolding of recombinant proteins
HRP20120522T1 (hr) * 2007-03-30 2012-08-31 Ambrx Modificirani fgf-21 polipeptidi i njihova uporaba
KR101530395B1 (ko) 2007-04-27 2015-06-19 피페넥스 인크. 향상된 수율 및(또는) 품질로 이종 단백질을 발현하는 특정 균주를 동정하기 위해 미생물 숙주를 신속히 스크리닝하는 방법
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
JP2010535781A (ja) 2007-08-03 2010-11-25 イーライ リリー アンド カンパニー 肥満に対する処置
WO2009117622A2 (en) * 2008-03-19 2009-09-24 Ambrx, Inc. Modified fgf-23 polypeptides and their uses
NZ590050A (en) * 2008-06-04 2012-08-31 Amgen Inc Fgf21 mutants and uses thereof
AU2016203765B2 (en) * 2008-10-10 2017-04-13 Amgen Inc. FGF21 mutants and uses thereof
WO2010042747A2 (en) * 2008-10-10 2010-04-15 Amgen Inc. Fgf21 mutants and uses thereof
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
JP5599822B2 (ja) * 2009-01-23 2014-10-01 ノヴォ ノルディスク アー／エス アルブミンバインダーａ−ｂ−ｃ−ｄ−ｅ−を有するｆｇｆ２１誘導体及びそれらの使用
JO3469B1 (ar) 2009-05-05 2020-07-05 Amgen Inc طافرات fgf21 واستخداماتها
EP2427207B1 (en) 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
WO2010142665A1 (en) * 2009-06-11 2010-12-16 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
JP2012530493A (ja) 2009-06-17 2012-12-06 アムジエン・インコーポレーテツド キメラポリペプチドおよびその使用
US8372952B2 (en) 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
EP2460527A1 (en) 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
WO2011130417A2 (en) 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
AU2011239386B2 (en) 2010-04-16 2015-03-19 Salk Institute For Biological Studies Methods for treating metabolic disorders using FGF
CN103415300B (zh) 2010-07-20 2018-02-23 诺沃—诺迪斯克有限公司 N‑末端修饰的fgf21化合物
CN103282055A (zh) * 2010-11-05 2013-09-04 CovX科技爱尔兰有限公司 抗糖尿病化合物
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
WO2012121428A1 (ko) * 2011-03-07 2012-09-13 주식회사 웰스킨 다이펩타이드를 유효성분으로 포함하는 섬유모세포 증식 조성물 및 상기 조성물을 포함하는 제품
UA118744C2 (uk) 2011-07-01 2019-03-11 ЕнДжиЕм БАЙОФАРМАСЬЮТІКАЛЗ, ІНК. Химерний пептид, композиція, що його містить, його застосування і способи лікування порушень і захворювань обміну речовин
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
UY34346A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
AR087973A1 (es) * 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
JP6165168B2 (ja) 2011-12-22 2017-07-19 ファイザー・インク 抗糖尿病化合物
US9475856B2 (en) 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
KR20150006059A (ko) 2012-06-11 2015-01-15 일라이 릴리 앤드 캄파니 섬유모세포 성장 인자 21 변이체
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
AU2013352363B2 (en) 2012-11-28 2018-04-12 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
NZ630469A (en) 2012-12-27 2017-02-24 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
EP3057605A1 (en) 2013-10-18 2016-08-24 Novartis AG Methods of treating diabetes and related disorders
CN105828833A (zh) 2013-10-21 2016-08-03 萨克生物研究学院 突变的成纤维细胞生长因子（fgf）1及使用方法
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
WO2015103782A1 (en) * 2014-01-13 2015-07-16 Wenzhou Medical College Biological Pharmaceuticals And Nature Products Ltd., Co Fgf21 mutant and conjugate thereof
HUE050279T2 (hu) 2014-01-24 2020-11-30 Ngm Biopharmaceuticals Inc Béta-klotho 2-es doménjéhez kötõdõ antitestek és azok alkalmazási módszerei
JP6712230B2 (ja) 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN104311656B (zh) * 2014-10-14 2017-04-05 哈尔滨博翱生物医药技术开发有限公司 cFGF‑21蛋白及其在治疗类风湿关节炎中的应用
KR102569907B1 (ko) 2014-10-23 2023-08-24 엔지엠 바이오파마슈티컬스, 아이엔씨. 펩티드 변이체를 포함하는 약제학적 조성물 및 그의 사용 방법
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
JP6727210B2 (ja) 2014-12-23 2020-07-22 ノヴォ ノルディスク アー／エス Ｆｇｆ２１誘導体及びその使用
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
JP2018535964A (ja) 2015-10-30 2018-12-06 ソーク インスティテュート フォー バイオロジカル スタディーズ 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
TW201731867A (zh) * 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
WO2017220706A1 (en) * 2016-06-22 2017-12-28 Novo Nordisk A/S Pharmaceutical compositions of fgf21 derivatives and uses thereof
AU2017315459B2 (en) 2016-08-26 2023-06-29 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
EP4470551A3 (en) 2017-03-14 2025-02-26 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
EP3619324B1 (en) 2017-05-05 2025-07-09 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
KR20200051706A (ko) 2017-09-08 2020-05-13 브리스톨-마이어스 스큅 컴퍼니 비알콜성 지방간염 (nash)을 치료하는 방법에 사용하기 위한 변형된 섬유모세포 성장 인자 21 (fgf-21)
CN111518770B (zh) 2017-12-19 2023-01-06 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
SI3727423T1 (sl) 2017-12-22 2024-08-30 Novartis Ag Zdravljenje metaboličnih motenj z različicami fgf21
US11679143B2 (en) 2018-02-08 2023-06-20 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
MX2021000016A (es) 2018-07-03 2021-03-09 Bristol Myers Squibb Co Formulaciones de factor de crecimiento de fibroblastos (fgf-21).
CN110791517A (zh) * 2018-08-01 2020-02-14 中国农业大学 成纤维细胞生长因子21的制备、纯化及其结晶
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
CN114853908B (zh) 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
IL294534A (en) 2020-01-08 2022-09-01 Bristol Myers Squibb Co Fgf-21 conjugate formulations
CN115322794B (zh) 2020-01-11 2025-09-19 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
JP7503148B2 (ja) * 2020-04-29 2024-06-19 ワンジーン バイオテクノロジー インコーポレイテッド 新規なタンパク質結合体、並びにその非アルコール性脂肪性肝炎、肥満及び糖尿病の予防または治療用途
JP2023538533A (ja) 2020-08-07 2023-09-08 ブリストル－マイヤーズ スクイブ カンパニー 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
WO2022115597A1 (en) 2020-11-25 2022-06-02 Bristol-Myers Squibb Company Methods of treating liver diseases
CN113633756A (zh) * 2021-06-17 2021-11-12 温州医科大学 Fgf21温敏缓释载体和基因修饰方法以及其制备方法
CN118063586B (zh) * 2024-04-03 2025-06-24 独步吾奇生物医疗科技(江苏)有限公司 一种人碱性成纤维细胞生长因子的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US7408047B1 (en) * 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
AU7368100A (en) 1999-09-10 2001-04-10 Curagen Corporation Fibroblast growth factor polypeptide and nucleic acids encoding same
WO2001032678A1 (en) 1999-11-05 2001-05-10 Smithkline Beecham Corporation sbgFGF-19a
AU1922101A (en) * 1999-11-18 2001-05-30 Chiron Corporation Human fgf-21 gene and gene expression products
US6716626B1 (en) * 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
WO2001049849A1 (en) 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf11
US20020001825A1 (en) 2000-03-31 2002-01-03 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
JP2004515216A (ja) 2000-06-06 2004-05-27 インサイト・ゲノミックス・インコーポレイテッド 細胞外メッセンジャー
US20050048507A1 (en) * 2001-01-11 2005-03-03 Mei Zhong Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
EP1469880A4 (en) 2002-01-15 2006-04-26 Lilly Co Eli METHOD FOR REDUCING MORBIDITY AND MORTALITY IN CRITELY SICK PATIENTS
BRPI0515252B1 (pt) * 2004-09-13 2018-02-06 Cooper Technologies Company Módulo e dispositivos de desconexão por comutação com fusível

Also Published As

Publication number Publication date
KR20060135648A (ko) 2006-12-29
TW200520772A (en) 2005-07-01
US20090118190A1 (en) 2009-05-07
JP2007535306A (ja) 2007-12-06
IL175736A0 (en) 2008-02-09
US7491697B2 (en) 2009-02-17
AR046877A1 (es) 2005-12-28
EA200601121A1 (ru) 2006-10-27
US20070142278A1 (en) 2007-06-21
NO20062662L (no) 2006-08-07
AU2004303783A1 (en) 2005-07-07
EP1702067A1 (en) 2006-09-20
WO2005061712A1 (en) 2005-07-07
JP4477013B2 (ja) 2010-06-09
EP2270163A1 (en) 2011-01-05
CA2549249A1 (en) 2005-07-07
CN1890371A (zh) 2007-01-03

Similar Documents

Publication Publication Date Title
BRPI0416683A (pt) muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
BRPI0514790A (pt) muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano
CN116115629A (zh) 核酸产品及其施用方法
BR122013003013B1 (pt) Proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
RU95113418A (ru) Полипептиды, способы получения, днк, вектор, клетка, применение полипептида, фармацевтические композиции
CN109477102A (zh) 核酸产品及其施用方法
NO974812L (no) Nytt protein og fremgangsmåte for fremstilling av dette
BR0207576A (pt) Variante glicosilada de um polipeptìdeo de interferon beta precursor (ifnb), processos de aumentar a glicosilação in vivo de uma molécula de ifnb precursora, de produzir uma molécula de ifnb glicosilada, para preparar uma variante conjugada e de tratar um mamìfero com esclerose múltiplam composição farmacêutica, molécula de ifnb variante, sequência de nucleotìdeo, vetor de expressão, célula hospedeira de glicosilação conjugado, e, uso de um conjugado
EA200800368A1 (ru) Гликозилированный il-7, получение и применение
PT804479E (pt) Método para o tratamento de diabetes mellitus utilizando kgf
MX2022007546A (es) Interferon-alfa-2 modificado que tiene inmunogenicidad reducida.
EP0785950B1 (en) Keratinocyte growth factor analogs
CA2692358A1 (en) Recombinant human interferon-like proteins
KR890700606A (ko) 생물학적 활성분자
DE60143561D1 (de) Nukleinsäuren kodierend für polypeptide mit chips aktivität
CN110078793B (zh) 一种具有抗衰老和修复作用的多肽及其用途
ATE175719T1 (de) Epididymis-spezifische polypeptide und deren verwendung
RU2004137000A (ru) Мутеины плацентарного фактора роста 1 типа, способ их получения и применение
CN118620084A (zh) 一种透皮型重组人源化胶原蛋白
JP2010500024A (ja) 強化された生物学的活性を有する組換えインターフェロン−β
KR102171363B1 (ko) 전구세포 또는 줄기세포 동원 활성을 가지는 물질 p 유사체 및 이를 포함하는 조성물
EP3500284A1 (en) Bovine fibroblast growth factor 21 and ketosis in dairy cattle
CA2616187A1 (en) Human growth hormone conjugated with biocompatible polymer
BRPI0415296A (pt) cdna modificado para os nìveis de expressão elevados do fator viii e seus derivados
JP2008518622A5 (pt)

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]